Haloperidol concentrations elevated in Chinese patients

Potkin, Steven G.; Shen, Yucun; Pardes, Herbert; Phelps, Bruce H.; Zeng, Dongfeng; Shen, Liang; Korpi, Esa R.

doi:10.1016/0165-1781(84)90017-9

Cited by 93 publications

(32 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For example, Chinese and Asian populations have a higher incidence of poor metabolizers, resulting in higher drug plasma levels. Chinese patients produce 40-50% higher plasma haloperidol concentrations compared to white and black patients [Potkin et al, 1984]. The cytochrome P450 isozymes CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 are primarily involved in SSRI metabolism, and the frequency of different alleles varies between different groups [Mancama and Kerwin, 2003].…”

Section: Discussionmentioning

confidence: 99%

Escitalopram in major depressive disorder: a multicenter, randomized, double-blind, fixed-dose, parallel trial in a Chinese population

et al. 2008

Self Cite

View full text Add to dashboard Cite

Escitalopram, the S‐enantiomer of citalopram and the most selective of the selective serotonin reuptake inhibitor (SSRI) has been shown to be efficacious in the treatment of major depression in white populations. Our aim in this study was to investigate the efficacy and tolerability of escitalopram in Chinese patients with moderate to severe major depression. Patients who met DSM‐IV criteria for a major depressive episode were enrolled in this multicenter, randomized, double‐blind, fixed‐dose comparison trial. Patients were given escitalopram 10 mg/day or fluoxetine 20 mg/day for 8 weeks. All patients were assessed with the 17‐item Hamilton Depression Rating Scale (HAM‐D‐17) and the Montgomery–Åsberg Depression Rating Scale (MADRS). Tolerability was assessed on the basis of adverse effects (measured with a locally developed checklist), regular biochemical tests, and electrocardiograph (ECG) assessments. Two hundred forty patients were enrolled and randomized to escitalopram (123 patients) or fluoxetine (117 patients). The HAM‐D‐17 total scores of both groups decreased significantly from baseline, but there was no significant difference at week 8 between the two groups (15.8 for escitalopram and 14.7 for fluoxetine; P >.05). There were no significant differences in response rates at all visits after treatment based on either HAM‐D‐17 or MADRS. A post hoc analysis indicated that escitalopram was superior to fluoxetine on two items of the HAM‐D‐17: “depressed mood” (P =.023) and “work and interest” (P =.024). The adverse events reported in the escitalopram and fluoxetine groups were comparable, and most were mild to moderate. Both drugs showed good compliance profiles. Escitalopram 10 mg/day is at least as efficacious as fluoxetine 20 mg/day and well tolerated in Chinese patients with major depression, with possible superiority in some core symptoms such as “depressed mood” and “work and interest.” Depression and Anxiety 0:1–9, 2006. © 2006 Wiley‐Liss, Inc.

show abstract

Section: Discussionmentioning

confidence: 99%

Escitalopram in major depressive disorder: a multicenter, randomized, double-blind, fixed-dose, parallel trial in a Chinese population

et al. 2008

Self Cite

View full text Add to dashboard Cite

show abstract

“…The collaboration of clinicians and neuroscientists makes the exploration of yet another explanation possible. If schizophrenic illness proves to be homogeneous across cultural groups, can differences in pharmacokinetics or pharmacodynamics help explain differences in therapeutic response (135,137,138)? If such differences are found, they might prove to have a genetic basis.…”

Section: Proposals For Future Researchmentioning

confidence: 99%

An Update on the Epidemiology of Schizophrenia^*

Beiser

Iacono

1990

Can J Psychiatry

View full text Add to dashboard Cite

While recent developments such as brain imaging and genetic linkage analysis have been rightly hailed as potential breakthroughs in the investigation of etiology, new technologies must not divert attention from basic problems which continue to hamper research in the field, or encourage the acceptance of overly simplistic answers to a complicated question. In order to study its etiology, a disorder must be clearly defined. While the precision of systems like the RDC (2) and the DSM-III-R (3) has improved diagnostic reliability, these systems are merely a convenient, shared illusion about how best to categorize a still elusive disorder. Conceptualizing the nature and critical features of schizophrenia is important to the mental health field.

show abstract

“…The mean daily dosage prescribed 0.2 mg/kg (range 0.05-0.42), was similar to the therapeutic dose generally prescribed to Caucasian patients (Altamura et al, 1988). In a comparative study, the HAL plasma concentration of the Orientals was reportedly 52 per cent higher than the Caucasians given similar doses of HAL (Potkin et al, 1984). In this study, the plasma concentrations of 12 patients (80 per cent) were in the purported ther- apeutic ranges of 5-1 5 ng/ml established in Caucasians (Volavka et al, 1987).…”

Section: Discussionmentioning

confidence: 77%

The plasma haloperidol and reduced haloperidol concentrations in chinese schizophrenic patients: Relationship between reduced haloperidol/haloperidol ratio and red blood cell haloperidol reductase activity

Wong

Chan

Wong

et al. 1992

Human Psychopharmacology

View full text Add to dashboard Cite

Fifteen Chinese schizophrenic patients were given titrated doses of haloperidol (0.05-0.42 mgikg) for two weeks. All these 15 patients were in clinical remission on maintenance dose of haloperidol. The mean plasma haloperidol and reduced haloperidol concentrations were 16.8 k 4.8 ng/ml and 13.6 f 5.7 ngiml respectively. The plasma RHAL/HAL ratio was in the range of 0.13-1.94. These values were similar to that reported for the Japanese population. The frequency distribution appeared to be bimodal. RBC reductase activity were found to be distributed normally and no correlation was found between plasma RHALiHAL ratio and RBC reductase activity.

show abstract

Haloperidol concentrations elevated in Chinese patients

Cited by 93 publications

References 11 publications

Escitalopram in major depressive disorder: a multicenter, randomized, double-blind, fixed-dose, parallel trial in a Chinese population

Escitalopram in major depressive disorder: a multicenter, randomized, double-blind, fixed-dose, parallel trial in a Chinese population

An Update on the Epidemiology of Schizophrenia^*

The plasma haloperidol and reduced haloperidol concentrations in chinese schizophrenic patients: Relationship between reduced haloperidol/haloperidol ratio and red blood cell haloperidol reductase activity

Contact Info

Product

Resources

About

Haloperidol concentrations elevated in Chinese patients

Cited by 93 publications

References 11 publications

Escitalopram in major depressive disorder: a multicenter, randomized, double-blind, fixed-dose, parallel trial in a Chinese population

Escitalopram in major depressive disorder: a multicenter, randomized, double-blind, fixed-dose, parallel trial in a Chinese population

An Update on the Epidemiology of Schizophrenia*

The plasma haloperidol and reduced haloperidol concentrations in chinese schizophrenic patients: Relationship between reduced haloperidol/haloperidol ratio and red blood cell haloperidol reductase activity

Contact Info

Product

Resources

About

An Update on the Epidemiology of Schizophrenia^*